Canagliflozin Alleviates Diabetic Cardiovascular Disease via Lipid Lowering, Mitochondrial Homeostasis, and Gut Microbiota Regulation

Xueliang Wang,Zhe Wang,Di Liu,Hao Jiang,Chao Cai,Guoyun Li,Guangli Yu

DOI: https://doi.org/10.21203/rs.3.rs-754308/v1

2021-08-12

Abstract:Abstract Background: Type 2 diabetes mellitus (T2DM) is associated with cardiovascular disease (CVD). Sodium glucose cotransporter 2 inhibitors (SGLT2i) represent the most effective oral drugs for the treatment of T2DM, and have been shown to improve generalized vascular dysfunction. However, it’s effect on improving diabetic CVD and the possible action mechanism are currently unclear. Methods: T2DM was induced by feeding a high-fat diet (HFD) to male C57BL/6J mice for 24 weeks. Afterthat, HFD-fed mice were treated with Cana (50 mg/kg/d) or positive drug metformin (225 mg/kg/d) by oral gavage for 6 weeks. Myocardial mitochondrial morphology and cardiovascular abnormalities were assessed by transmission electron microscope and histological staining; lipids profile and oxidative stress state were assessed by corresponding biochemical assay kits and histological staining; myocardial injury was characterized by H&E staining, TUNEL, and ELISA assays; colonic gut microbiota was assessed by 16S rDNA high-throughput sequencing. Results: Cana reduced the lipid (such as TG, TC, and LDL-C) accumulation in serum, thus decreased atherogenic index of plasma and arteriosclerosis index values. And, Cana reduced the circulating markers of inflammation (such as TNFα, MCP-1, and IL-6). More importantly, Cana improved cardiac mitochondrial homeostasis and relieved oxidative stress. Myocardial injury was alleviated after Cana treatment with decreasing levels of serous cTn I and sCD40L. Thus, cardiovascular abnormality was relieved by elevating the CD31 expression level, and suppressing fibrosis and basement membrane thickening in T2DM mice. Interestingly, Cana administration increased the ratio of Firmicutes/Bacteroidetes and the relative abundance of Olsenella , Alistipes , and Alloprevotella , while decreased the abundance of Proteobacteria, Helicobacter and Mucispirillum at various taxonomic levels. Conclusions: Cana treatment improved CVD by decreasing the risk of atherosclerosis, maintaining a relatively normal haemogram, and reducing the thickness of vascular basement membrane and myocardial injury. Importantly, Cana treatment significantly elevated myocardial mitochondria homeostasis, thus ameliorated the oxidative stress and inflammatory states. Moreover, Cana subtly altered microbiota composition in T2DM mice with CVD, which contributed to the improvement of CVD. Collectively, the improvements of myocardial mitochondrial and gut microbiota homeostasis, may represent an important mechanism underlying the cardiovascular benefits of Cana treatment.